Single-arm, Open-label Phase II Efficacy Study of First-in-class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma

Grant

Date/time Interval

  • November 3, 2017 - April 30, 2021

    • Awarded By

    Total Award Amount

  • 21000.00

    • Direct Costs

  • 10815.00

    • Sponsor Award Id

  • ABTC1602

    • Contributor

  • Hassan Fathallah-Shaykh M.D., Ph.D.   Investigator  
  • Louis Nabors M.D.   Principal Investigator  
  • Xiaosi Han   Investigator